Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
Kinan Alhallak, Jennifer Sun, Amanda Jeske, Chaelee Park, Jessica Yavner, Hannah Bash, Berit Lubben, Ola Adebayo, Ayah Khaskiah, Abdel Kareem Azab
Abstract
MM is the second most common hematological malignancy and represents approximately 20% of deaths from hematopoietic cancers. The advent of novel agents has changed the therapeutic landscape of MM treatment; however, MM remains incurable. T cell-based immunotherapy such as BTCEs is a promising modality for the treatment of MM. This review article discusses the advancements and future directions of BTCE treatments for MM.
Topics & Concepts
MedicineTreatment modalityMalignancyMultiple myelomaImmunotherapyModality (human–computer interaction)OncologyInternal medicineCancerComputer scienceArtificial intelligenceCAR-T cell therapy researchMonoclonal and Polyclonal Antibodies ResearchMultiple Myeloma Research and Treatments